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of the Creative Com
share the work provObjective: Cigarette smoking during pregnancy increases risks of poor pregnancy
outcomes including miscarriage and stillbirth (pregnancy loss), but the effect of smoking
on pregnancy loss among HIV-infected women has not been explored. Here, inves-
tigated the impact of smoking on risk of pregnancy loss among HIV-positive and
HIV-negative women, and estimated the potential impact of realistic smoking cessation
interventions on risk of pregnancy loss among HIV-positive women.
Design: We analyzed pregnancy outcomes in HIV-positive and HIV-negative partici-
pants in the Women’s Interagency HIV Study between 1994 and 2014.
Methods: We estimated effects of current smoking at or immediately before pregnancy
on pregnancy loss; we controlled for confounding using regression approaches, and
estimated potential impact of realistic smoking cessation interventions using a semi-
parametric g-formula approach.
Results: Analysis examined 1033 pregnancies among 659 women. The effect of
smoking on pregnancy loss differed dramatically by HIV status: adjusted for confound-
ing, the risk difference comparing current smokers to current nonsmokers was 19.2%
(95% confidence limit 10.9–27.5%) in HIV-positive women and 9.7% (95% confi-
dence limit 0.0–19.4%) in HIV-negative women. These results were robust to sensitivity
analyses. We estimated that we would need to offer a realistic smoking cessation
intervention to 36 women to prevent one pregnancy loss.
Conclusion: Smoking is a highly prevalent exposure with important consequences for
pregnancy in HIV-positive pregnant women in the United States, even in the presence of
potent highly active antiretroviral therapy. This evidence supports greater efforts to
promote smoking cessation interventions among HIV-positive women, especially those
who desire to become pregnant.
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554 AIDS 2017, Vol 31 No 4IntroductionCigarette smoking during pregnancy is a risk factor for
poor pregnancy outcomes including low birthweight,
stillbirth, and neonatal morbidity and mortality [1,2].
Evidence demonstrating an association between cigarette
smoking and miscarriage (spontaneous abortion) is less well
established but strong: the surgeon general said in 2014 that
the ‘evidence is suggestive, but not sufficient, to infer a
causal relationship between maternal active smoking and
spontaneous abortion’ [1]. A recent meta-analysis found
that risk of miscarriage (defined as pregnancy loss up to 28
weeks gestation) among women who smoked during
pregnancy was 1.32 (95% confidence limit 1.21–1.44)
times the risk among nonsmoking women, with increasing
risks associated with increased cigarette consumption [3].
These results are consistent with the results of earlier meta-
analyses [4,5]. The biological mechanism explaining how
smoking might lead to miscarriage remains unclear [1], but
hypotheses include fetal hypoxia and changes in placental
vasculature [6–9], inflammation [10–14], and immune
modulation [13,15].
Smoking is highly prevalent among women living with
HIV in the United States. A recent large-scale study
found that approximately 35% of women receiving HIV
care in the US report current smoking, about twice the
prevalence in the general population [16]. In addition,
women with HIV infection may be less likely to cease
smoking than other women [17].
Women living with HIV are now being diagnosed and
initiated on treatment earlier, which has resulted in longer
life expectancy, healthier lives, and a significantly
decreased rate of mother-to-child transmission. This
has influenced conception choices and pregnancy rates
among HIV-positive women [18]. However, HIV
infection has been associated with an increased risk of
miscarriage [19] potentially due to chronic inflammation
associated with long-term HIV infection or effects of
HIV on the immune system [18,20,21].
Given that both HIV infection and smoking are associated
with inflammation and immune activation [22–24], it is
plausible that HIV and smoking might interact to place
HIV-infectedwomenwho smoke at higher-than-expected
risk for miscarriage. To date, there has been little research
examining the effect of smoking on pregnancy loss among
HIV-infected women. Although the causes of miscarriage
among HIV-infected women were previously examined in
the Women’s Interagency HIV Study (WIHS) [20], effect
of smoking on miscarriage was not explicitly investigated.
A recent report demonstrated increased morbidity
among infants of HIV-positive smokers compared with
those of HIV-positive nonsmokers, but this study did
not examine miscarriage [2] nor did a study that found
positive associations between smoking and adverse birth
outcomes [25].Here, we investigated the effect of smoking on risk of
miscarriage or stillbirth (hereafter, pregnancy loss) among
participants of the WIHS from 1994 until 2014. We also
examined differences in the effects of smoking on
pregnancy loss by HIV status. Finally, we quantified the
potential impact of a realistic intervention for smoking
cessation on total rates of pregnancy loss [26–28].
Notably, recent research in the WIHS found that
pregnancy is associated with a decreased time to smoking
cessation [27], pointing toward the potential for effective
interventions in this population.Methods
Main data source
The WIHS is a multicenter prospective observational
cohort study of HIV-positive and sociodemographically
matched HIV-negative women enrolled in 10 cities
throughout the United States. WIHS participants
undergo twice-yearly medical examinations and inter-
views; detailed procedures are described elsewhere
[29,30]. WIHS enrollment occurred after approval by
each site’s institutional review board and the WIHS
Executive Committee. All participants provided written
informed consent. These analyses were reviewed and
approved by the UNC Office of Human Research Ethics.
Outcome, exposure, covariates
The primary objective was to examine whether the
impact of smoking on pregnancy loss in the WIHS cohort
differed by HIV status. Smoking, HIV status, and birth
outcomes were obtained from the study database.
WIHS participants were eligible for this study if they
reported miscarriage (pregnancy loss before 20 weeks),
stillbirth, or live birth at a study visit between 1994 and
2014. Pregnancy outcomes coded as therapeutic abortion
(32% of outcomes), ectopic pregnancy (3%), other (1%),
or missing (including responses skipped, refused, or
answered as ‘Don’t know’, 1%) were excluded as
uninformative for the purpose of assessing the effect of
smoking on the pregnancy loss.
The main exposure for this study was cigarette smoking
during or immediately prior to pregnancy, which we
referred to as ‘current cigarette smoking’. To capture this
exposure, we used self-reported smoking status recorded
at the visit immediately prior to the visit at which the
pregnancy outcome was documented. This lagging of
the exposure ensured that the exposure preceded the
outcome in time; however, note that this visit was
between approximately 0–6 months before the preg-
nancy outcome, and may or may not have been during
pregnancy. When this one-back visit was missing (because
the participant missed a WIHS visit) we took smoking
status from the two-back visit; when the one-back and
two-back visits were missing, we took the smoking status
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(zero-back). Implications of this coding scheme were
examined in sensitivity analysis (see below).
Additional covariates likely to confound the exposure-
outcome relationships of interest were identified through
use of a causal directed acyclic graph [31]. Fully adjusted
models controlled for HIV status, age, race, employment
status, above-median income, BMI, depression, and
recent use of intravenous and nonintravenous drugs,
marijuana, and alcohol. These variables were all captured
at the same visit as the exposure information was
captured, and were generally modeled as categorical
variables; age and BMI were modeled as restricted
quadratic splines [32]. In sensitivity analysis, we examined
impact of specific nonintravenous drugs (see below).
We did not adjust for a history of smoking prior to main
exposure in the main analyses because among women
without a history of smoking, only two women reported
smoking during pregnancy; thus, there were near-empty
cells in the table of smoking history and current smoking
[33]. However, in sensitivity analyses we restricted the
sample to only those women with a history of smoking to
examine the possible impact of smoking history on
pregnancy loss via sustained inflammatory and metabolic
effects [34,35]. We also did not control for history of
pregnancy loss in the main analyses: smoking exposure
during prior pregnancies was not available for reported
pregnancies occurring prior to WIHS enrollment, and
controlling for prior outcomes without controlling for
prior exposure might increase rather than decrease bias
[36]. We included an indicator of a history of miscarriage
in a sensitivity analysis. We did not control for bacterial
vaginosis in main analysis, because smoking appears to
increase risk of this condition, and thus this condition
seems more likely to be a mediator of the smoking-
pregnancy loss relationship than a confounder [37];
however, we controlled for bacterial vaginosis concurrent
with smoking exposure in a sensitivity analysis. Finally,
very few of these pregnancies were exposed to diabetes or
common sexually transmitted infections (STIs) (gonor-
rhea, chlamydia, syphilis) so these potential confounders
were not included in models.
Main analyses
The two main analyses were the total impact of smoking
on pregnancy loss among all women (analysis 1) and
stratifying by HIV infection status (analysis 2).
Sensitivity analyses
We conducted several sensitivity analyses. We restricted
analysis to only those women with a documented history
of smoking, and extended this analysis to control for any
history of miscarriages or stillbirths. We considered main
effects overall and by HIV status among 327 women who
reported no prior pregnancies of any kind during or
previous to participation in the WIHS. We limited tomore-recent pregnancies (pregnancies since 1998; preg-
nancies since 2002) to explore time-sensitivity of results.
We examined the impact of adjustment for presence of
bacterial vaginosis. Additionally, among HIV-positive
women, we examined effect measure modification by use
of any ARTand separately by use of HAART, and by viral
suppression status controlling for HAART use. We also
analyzed restricting to individuals with exposure
and covariates measured exactly one visit before the
pregnancy outcome, to minimize measurement error;
and separately restricting to individuals with exposure
and covariates measured exactly two visits before the
pregnancy outcome, to clarify sensitivity of the results to
exposure timing. Finally, we adjusted for recent use
of cocaine and methamphetamine, rather than for
nonintravenous drugs in general. In general, sensitivity
analyses adjusted for a reduced set of confounders to
ensure model convergence.
Statistical approach
For all analyses, we used multiple linear regression to
estimate adjusted risk differences for the risk of pregnancy
loss comparing current smokers to current nonsmokers
among WIHS participants, both overall and by HIV
infection status. We focus primarily on the estimation of
risk differences rather than risk or odds ratios because we
are primarily interested in population impact of smoking
on pregnancy loss; it is generally thought that absolute
measures such as risk differences quantify impact better
than ratio measures [38–40]. We controlled for all
variables noted above; when the resulting model did
not converge, we used backwards elimination methods
to reduce the model to key confounders. All models
allowed multiple pregnancies/outcomes per woman; we
used a generalized estimating equations approach with
an exchangeable correlation structure to account for
within-woman correlations.
Population intervention analyses
The analyses described above attempt to estimate causal
effect of smoking exposures, but do not map directly onto
potential interventions to reduce impact of smoking in
the population [26,28,41]. We estimate several additional
risk differences that point toward effects of interventions
on smoking among HIV-positive women (only) in this
setting. Specifically, we estimate a population attributable
risk difference, which contrasts the risk of pregnancy loss
observed in the data to a population in which, counter to
fact, no women reported current smoking. Then we
estimate a generalized intervention risk difference, which
contrasts the risk of pregnancy loss observed in the data to
a population in which current smoking is reduced by
means of a smoking cessation intervention, which could
be broadly implemented under real-world conditions.
Specifically, we estimated the expected impact of
applying the intervention described by Hoffman et al.
[42] and tested in the WIHS population by Redding et al.
[43], which yielded a quit rate of 13.6%. These analyses
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Table 1. Characteristics of Women’s Interagency HIV Study
participants measured before or at time of pregnancy outcomes in







Age (years)a 30.2 (25.6, 34.8) 28.7 (24.6, 32.5)
Black race 253 (67%) 372 (57%)
Hispanic ethnicity 86 (23%) 223 (34%)
Socioeconomic status
Employed 74 (20%) 267 (41%)
Currently has health
insurance
300 (80%) 569 (87%)
Income above median 116 (31%) 355 (54%)
Completed high
school








166 (44%) 173 (26%)
Intravenous drug use 8 (2%) 4 (1%)
Nonintravenous drug
use
145 (38%) 78 (12%)
Marijuana use 114 (30%) 70 (11%)
Intravenous drug use at
baselineb
63 (17%) 34 (5%)
Clinical indicators
HIV-positive 212 (56%) 380 (58%)
Number of previous
pregnanciesa
1.0 (1.0, 2.0) 1.5 (1.0, 2.0)
BMIa 27.4 (23.4, 32.9) 29.2 (25.4, 34.0)
Depression (CESD 
16)
166 (44%) 159 (24%)
Bacterial vaginosis 77 (20%) 57 (9%)
Data represent 1033 outcomes among 659 individual participants.
CESD, Center for Epidemiologic Studies Depression (Scale). Table
contents are counts (%) except.
aReported as median (Q1, Q3).
bReported as HIV risk category even among women without HIV.were performed using the parametric g-formula, a
statistical method that can be used to simulate cohort
experiences under well defined interventions [28,44,45].
We validated that the g-formula fit while ignoring
repeated measures gave similar results compared with the
main analysis; for computational simplicity we proceeded
ignoring repeated measures.Results
There were 1033 pregnancies with outcomes of live birth,
stillbirth, or miscarriage reported among 659 women in
the WIHS between 1994 and 2014. Characteristics of
WIHS participants before or at the time of pregnancy by
current smoking status are shown in Table 1. Current
smokers during pregnancy were more likely to be black
and to be unemployed, and less likely to have completed
high school than women who did not smoke during
pregnancy. In addition, smokers were far more likely than
nonsmokers to report recent alcohol and nonintravenous
drug use including marijuana. depressive symptoms[Center for Epidemiologic Studies Depression (Scale)
 16] were twice as common among smokers compared
with nonsmokers. HIV status was similar for women who
smoked and women who did not smoke during
pregnancy. Only six women reported diabetes at the
visit previous to pregnancy outcome.
Characteristics of HIV-positive women (n¼ 396) at the
time of their 592 pregnancies are described in Table 2.
Similar to findings for the combined study sample, HIV-
positive pregnant women who currently smoked were
also more likely to report recent alcohol consumption and
nonintravenous drug use compared with HIV-positive
pregnant women who did not smoke. HIV-positive
women who smoked during pregnancy were also less
likely to report current use of antiretroviral therapy and
were less likely to be virally suppressed.
Thirty-two percent of all pregnancies in the study sample
resulted in pregnancy loss, including 314 miscarriages and
12 stillbirths. The effect of smoking on risk of pregnancy
loss is reported in Table 3. Adjusted for confounding,
the estimated risk difference of current smoking on risk
of miscarriage was 15.1% (95% confidence limit 8.4–
21.9%), indicating that current smokers were 15% more
likely to report a miscarriage compared to current
nonsmokers (Table 3). These effects were largely robust to
sensitivity analysis, and appeared slightly higher among
women with a history of smoking (Table 3).
The overall risk of pregnancy loss was similar by HIV
status: 30% among HIV-negative women, and 33%
among HIV-positive women. In smoking-unexposed
pregnancies, unadjusted (crude) risk of pregnancy loss was
approximately the same in HIV-positive and HIV-
negative women (22 and 25%, respectively), whereas in
smoking-exposed pregnancies, crude risk of pregnancy
loss was higher in HIV-positive women (52%) than in
HIV-negative women (33%).
Consistent with these crude findings, the adjusted effect
of smoking on pregnancy loss differed dramatically by
HIV status (Table 4; interaction P¼ 0.1169): the adjusted
risk difference for smokers vs. not nonsmokers was larger
in HIV-positive women (risk difference¼ 19.2%; 95%
confidence limit 10.9–27.5%) than HIV-negative
women (risk difference¼ 9.7%, 95% confidence limit
0.0–19.4%) (Table 4). Women living with HIV, women
on HAART, and separately virally suppressed women
(controlling for use of HAART) experienced larger
impacts of smoking on pregnancy loss; results were also
higher among women with a history of smoking (Table
4). Results were largely robust to sensitivity analyses,
including restriction to women with exposure measured
one visit, or alternatively two visits, before pregnancy
outcome (not shown) and when controlling for cocaine
or methamphetamine use rather than nonintravenous
drugs in general (not shown). For comparison with
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Table 2. Selected characteristics of 592 pregnancies among 396 HIV-positive women participating in the Women’s Interagency HIV Study
between 1994 and 2014, measured before or at pregnancy outcome.a
Characteristic Current smoker n¼212 Current nonsmoker n¼380
Substance use since last visit
Alcohol consumption (any) 89 (42%) 81 (21%)
Intravenous drug use 4 (2%) 3 (1%)
Nonintravenous drug use 76 (36%) 31 (8%)
Marijuana use 52 (25%) 28 (7%)
Clinical indicators
Current use of ART 141 (67%) 305 (80%)
Current use of HAART 96 (45%) 258 (68%)
Viral load <1000 copies/ml 102 (48%) 270 (71%)
CD4þ cell count (cells/ml; most recent)a 412 (283, 599) 485 (325, 679)
Table contents are counts (%) except. Clinical indicators measured concurrently with smoking exposure.
aReported as median (Q1, Q3).previous work, we also calculated the adjusted risk ratios
for the effect of smoking on pregnancy loss: in HIV-
negative women, the risk ratio was 1.31 (95% confidence
limit 0.99–1.75) and in HIV-positive women the risk
ratio was 1.74 (95% confidence limit 1.36–2.23).
Population intervention estimates
The overall risk of miscarriage in the 592 women living
with HIV was 33%. We then estimated among
women living with HIV, the population attributable risk
difference comparing the observed data with a hypothe-
tical population in which no one smoked was 6.8% (95%
confidence limit 3.3–10.4%). The risk difference
comparing risk of pregnancy loss in the observed dataTable 3. Impact of smoking status (current smokers vs. current
nonsmoker) on risk of miscarriage or stillbirth among Women’s



















1.3 First pregnancy 15.6 4.9–26.2
1.4 Pregnancies on or after
1 January 1998 12.6 5.1–20.1




All models account for repeated outcomes within women. WIHS,
Women’s Interagency HIV Study.
aFully adjusted models controlled for HIV status, age, socioeconomic
status (employment, race, income), BMI, depression, recent use of
intravenous drugs, marijuana, and alcohol. Modeling details given in
text.
bSensitivity analyses relied on a reduced model for convergence. The
main reduced adjusted model controlled for HIV status, depression,
recent use of marijuana and alcohol.with the risk in a hypothetical population in which
current smoking was less prevalent by approximately 14%
points due to a realistic smoking cessation intervention
was 1.0% (0.4–1.7%).Discussion
This study estimates the effects of smoking prior to or early
in pregnancy on risk of pregnancy loss (primarily
miscarriage) among HIV-positive as well as HIV-negative
pregnant women. We found strong evidence that current
smoking at the visit prior to pregnancy increased risk
of pregnancy loss in both HIV-positive and HIV-negative
women. We also found that the effect of smoking
was substantially stronger among HIV-positive women,
a finding robust to sensitivity analysis. We note that the
P value for the statistical interaction of smoking and HIV did
not reach significance at an a of 0.05 in main analysis;
however, wewere more concerned with estimation of effect
size than with testing significance in this work [46,47].
One possible explanation for the strong effect of smoking
on pregnancy loss risk among HIV-positive women is
synergism due to inflammation, which is characteristic of
both smoking and long-term HIV infection, although
other results (Table 4) complicate this explanation. The
lack of clear mechanism by which smoking apparently
dramatically increases risks of pregnancy loss points
toward future areas of research.
Nonetheless, in the present data we can consider to what
extent smoking cessation interventions could reduce
incidence of pregnancy loss in this population. Here, we
calculated risk differences for smoking cessation inter-
ventions among HIV-positive women in the WIHS.
Under the assumption that the intervention of Hoffman
et al. [42] would work similarly in other WIHS sites as it
did in Chicago [43], we calculated that universal
application of this intervention could result in a risk
difference of about 1.0% in the entire population. In the
WIHS, for every 100 pregnancies, about (212/592¼) 36
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Table 4. Impact of smoking status (current smoking, yes/no) on risk of miscarriage or stillbirth among Women’s Interagency HIV Study












Crude 15.0 4.9 to 25.1 30.0 21.9 to 38.2
Adjusteda 9.7 0.0 to 19.4 19.2 10.9 to 27.5
Sensitivity analysesb
Adjusted, reduced modelb 8.8 0.9 to 18.5 21.5 13.3 to 29.8
2.1 Subjects with smoking history 14.2 3.0 to 25.4 24.0 14.1 to 33.9
2.2 Subjects with smoking history and
control for previous pregnancy loss
13.0 2.6 to 23.4 23.9 14.0 to 33.7
2.3 First pregnancy 7.3 7.7 to 22.3 23.5 9.7 to 37.2
2.4 Pregnancies on or after . . .
1 January 1998 4.2 6.4 to 14.8 19.7 9.9 to 29.5
1 January 2002 5.5 6.4 to 17.4 23.7 12.6 to 34.8
2.5 Controlling for bacterial vaginosis 8.0 1.5 to 17.5 19.2 11.0 to 27.3
2.6 By ART usec
Current ART 20.4 10.4 to 30.5
No current ART 17.5 1.9 to 33.1
2.7 By HAART usec
Current HAART 24.0 13.0 to 35.1
No current HAART 13.4 0.4 to 26.5
2.8 By viral suppression statusd
Suppressed 22.5 11.1 to 33.9
Not suppressed 13.4 0.6 to 26.3
All models account for repeated outcomes within women.
aFully adjusted models controlled for HIV status (including an interaction term with main exposure), age, socioeconomic status (employment, race,
income), BMI, depression, recent use of intravenous drugs, marijuana, and alcohol. Modeling details given in text.
bSensitivity analyses relied on a reduced model for convergence. The main reduced adjusted model controlled for HIV status (including an
interaction term with main exposure), depression, recent use of marijuana and alcohol.
cThis model did not control for viral load or CD4þ cell count, which are affected by ART/HAART use in the last six months.
dModel also controlled for use of HAART. Suppression was defined as a viral load <1000 copies/ml.are in smokers. Since the intervention in question only
applies to smokers, the number needed to treat is
approximately 36; that is, applying this intervention to 36
smokers would result in one fewer miscarriage. This
number needed to treat is based on critical assumptions
including no uncontrolled confounding and correct
model specification [48,49], which cannot be verified
empirically in observational data. As such, this estimate
should be interpreted cautiously.
The interventional estimation also assumed that there
were no relevant side-effects of smoking cessation, and
that immediate smoking cessation at the visit previous to
the pregnancy outcome will be sufficient to affect the
pregnancy outcome. This latter assumption is especially
important given recent findings in the WIHS that
pregnancy is associated with a decreased time to smoking
cessation [27]. We examined this assumption by looking
only at HIV-positive women who reported current
smoking two visits before pregnancy outcome (n¼ 170),
we compared the 139 women who continued smoking to
the 31 who reported no smoking at one visit before
pregnancy outcome. While the results were imprecise due
to small numbers, they were below the null. This suggests
that short-term interventions might indeed be effective at
removing substantial risk of pregnancy loss, although
more work is needed to validate this claim.Additional limitations include the following. Pregnancy
losses are self-reported and it is likely that numerous early
miscarriages were not reported and that some presumed
miscarriages were not actual pregnancies. However, to
negate the main findings of this study, smoking would
have to be dramatically protective against early pregnancy
losses, which seems unlikely [3]. Likewise, unmeasured
confounding (e.g. smoking history, caffeine use,
additional coinfections not addressed above) is a threat
to our findings, but given their magnitude a confounder
(or group of confounders) having this impact seems
implausible. Another potential limitation of this work is
external validity [50,51]. HIV-negative women in the
WIHS are not necessarily representative of the general
population of HIV-negative women, as participants with
a history of drug use and other risk behaviors were
recruited as controls in WIHS. However, the adjusted risk
ratio for smoking calculated among HIV-negative women
is 1.35 and is comparable to the recently reported meta-
analytic estimate of 1.32 [3].
This analysis has numerous strengths. The WIHS is one of
the largest and longest running studies of HIV-positive
women in the world, and has well validated data collection
procedures. Because of the ethical impossibility of
randomizing smoking or HIV infection, such large
prospective cohort studies are the gold standard for
Smoking, HIV, and risk of pregnancy loss Westreich et al. 559addressing the question we sought to answer in this report.
Additionally, the inclusion of HIV-negative controls
within the WIHS allowed us to directly estimate how
smoking is modified by HIV infection. While there remain
threats to the validity of every study – observational or
randomized – our extensive sensitivity analyses support
our main findings. Finally, our estimate of the potential
effectiveness of a real-world intervention for smoking
cessation is novel, and points to concrete next steps that
could possibly address these issues more broadly.
In summary, we found that smoking is associated with
large absolute increases in risk of pregnancy loss, that
increases in risk are substantially larger among HIV-
positive than HIV-negative women, and that realistic
interventions can potentially lead to reduced incidence of
pregnancy loss. Taken in concert with evidence from
HIV-negative populations, this suggests that HIV-positive
women planning a pregnancy should be strongly
encouraged to cease smoking and supported in their
efforts to do so, for their own health and to increase the
probability of live birth.Acknowledgements
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